BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20842122)

  • 21. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
    Yoshimi A; Goyama S; Watanabe-Okochi N; Yoshiki Y; Nannya Y; Nitta E; Arai S; Sato T; Shimabe M; Nakagawa M; Imai Y; Kitamura T; Kurokawa M
    Blood; 2011 Mar; 117(13):3617-28. PubMed ID: 21289308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EVI1 drives leukemogenesis through aberrant ERG activation.
    Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
    Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR.
    Boyd KE; Xiao YY; Fan K; Poholek A; Copeland NG; Jenkins NA; Perkins AS
    Blood; 2006 Jan; 107(2):733-41. PubMed ID: 16204320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A critical role of epigenetic inactivation of miR-9 in EVI1
    Mittal N; Li L; Sheng Y; Hu C; Li F; Zhu T; Qiao X; Qian Z
    Mol Cancer; 2019 Feb; 18(1):30. PubMed ID: 30813931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
    Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
    Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.
    Chen P; Price C; Li Z; Li Y; Cao D; Wiley A; He C; Gurbuxani S; Kunjamma RB; Huang H; Jiang X; Arnovitz S; Xu M; Hong GM; Elkahloun AG; Neilly MB; Wunderlich M; Larson RA; Le Beau MM; Mulloy JC; Liu PP; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(28):11511-6. PubMed ID: 23798388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
    Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
    Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.
    Wieser R
    Gene; 2007 Jul; 396(2):346-57. PubMed ID: 17507183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.
    Yuasa H; Oike Y; Iwama A; Nishikata I; Sugiyama D; Perkins A; Mucenski ML; Suda T; Morishita K
    EMBO J; 2005 Jun; 24(11):1976-87. PubMed ID: 15889140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloid transforming protein Evi1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/Mi-2/NuRD.
    Spensberger D; Vermeulen M; Le Guezennec X; Beekman R; van Hoven A; Bindels E; Stunnenberg H; Delwel R
    Biochemistry; 2008 Jun; 47(24):6418-26. PubMed ID: 18500823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells.
    Cardona ME; Simonson OE; Oprea II; Moreno PM; Silva-Lara MF; Mohamed AJ; Christensson B; Gahrton G; Dilber MS; Smith CI; Arteaga HJ
    Leuk Lymphoma; 2016; 57(1):183-92. PubMed ID: 25907616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
    Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
    J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia.
    Su G; Lian X; Tan D; Tao H; Liu H; Chen S; Yin H; Wu D; Yin B
    Leuk Lymphoma; 2015 Feb; 56(2):472-9. PubMed ID: 24828867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.
    Li F; He W; Geng R; Xie X
    Clin Transl Oncol; 2020 Jan; 22(1):137-143. PubMed ID: 31054042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
    Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
    Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1(high) leukemia cells.
    Ichihara E; Kaneda K; Saito Y; Yamakawa N; Morishita K
    Biochem Biophys Res Commun; 2011 Dec; 416(3-4):239-45. PubMed ID: 22033412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
    Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
    Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
    Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
    Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
    Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
    PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
    Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
    Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.